reason report
price chang estim chang analysi
reiter rate increas former
price target per share guidanc appear
conserv term constant currenc revenu growth
also relat adjust margin result remain
optimist compani favor posit either deliv
upper-bound exceed corpor guidanc moreov realiz
oper leverag stand increas year-over-year
potenti enabl achiev lrp target adjust gross
margin adjust oper margin
rang exit although valuat
consolid base conserv natur initi guid
guidanc opinion proven surpris
expect on-going capit gain growth like acceler multipl
expand accordingli reiter rate revis
price target
increas price increas former
price target per share recal former
month price target assum revenu ebitda non-
earn multipl respect
revis price target assum like multipl
approxim respect
chang estim increas former
million revenu estim million maintain
non-gaap ep estim
moder former revenu estim million
increas former per share non-gaap ep estim
per share figur estim tabl left
rel valuat summari share current valu
revenu ebitda
peer trade like multipl respect
teleflex inc headquart wayn pa
lead global medic technolog hospit suppli
compani manufactur market clinic
differenti dispos product design use
oper critic care set addit
act oem supplier
import disclosur analyst certif page report access current disclosur stephen
inc cover compani client may refer
guidanc establish establish constant currenc revenu guidanc rang
unfavor fx headwind forecast reduc report revenu growth result compani forecast
report revenu growth rang impli report revenu million
million pre-cal consensu million specif take mid-point compani constant currenc
guidanc growth attribut urolift compani expect realiz annual growth
upc acquisit impli balanc core busi realiz constant currenc
growth addit compani revenu guidanc assum million million headwind
due continu disrupt steril issu million million headwind coronaviru
compani establish adjust gross margin guidanc rang impli
annual gross margin expans addit establish adjust oper margin guidanc rang
impli annual oper margin expans result compani establish
adjust ep guidanc rang per share per share pre-cal consensu per share
impli annual growth deriv adjust ep guidanc compani assum follow
increment contribut adjust ep per share per share oper per
share per share lower interest expens per share per share higher tax
per share increas weight averag share count per share fx headwind
headwind coronaviru effect assum resolv enter april
summari review tfx total revenu million pre-cal consensu million increas
report constant currenc basi versu prior year period quarterli adjust gross margin
increas repres record compani driven increas sale volum favor
sale mix benefit restructur price tfx record adjust oper margin increas
year year compani report adjust ad per share compani adjust
ep result report non-gaap earn growth per share figur
sale primari busi segment global vascular access revenu million increas term
constant currenc report global intervent revenu million increas
constant currenc basi report global surgic realiz revenu million increas
constant currenc basi report global anesthesia declin constant currenc basi
report million global intervent urolog increas constant currenc basi
report million revenu decreas constant currenc basi report
million oem revenu increas constant currenc basi report million
sale geograph segment america sale increas constant currenc basi
report million driven intervent urolog surgic intervent access vascular access
revenu emea region declin constant currenc basi report million
partial due time phase select distributor order lastli asia revenu million increas
constant currenc basi report led growth intervent access anesthesia furthermor
growth asia region driven china grew off-set weak australia new zealand
india
acquisit updat conjunct earn releas announc acquisit iwg high
perform conductor inc privat market leader insul ultra fine wire polyimid polym micro-
diamet tube compon million impli valuat revenu
ebit importantli acquisit fill product gap within oem franchis expect accret
averag revenu growth oper margin profil adjust ep furthermor compani address
follow end market embol protect tavr ep map cathet radiofrequ probe
pacemak lead hear aid picc cathet
pipelin remain on-track chose launch oper period origin plan
order prevent potenti disrupt urolift strong sale growth momentum compani pull forward
addit rep oper period importantli anticip commerci urolift
full convers complet addit compani announc nationwid
direct consum pilot digit cabl start oper period repres materi step
dtc effort compani dtc campaign sole focus region compani continu
target approv urolift japan estim billion commerci
furthermor complet compani limit market releas manta oper period full
commerci launch januari importantli penetr compani target market
million million anticip penetr impli revenu contribut
million assum mid-point compani target market opportun recal follow on-going discuss
fda receiv addit question agenc regard ez-plaz oper period
result compani delay plan bla submiss importantli compani complet
requisit test meet fda plan april note model continu reflect
contribut relat devic sale compani long rang plan includ million contribut
balanc sheet review oper period gener million oper cash flow bring
total oper cash flow year million result compani exit million
cash cash equival million debt yield net debt posit million accordingli
tfx credit facil defin leverag ratio stood approxim cye follow compani complet
hpc acquisit februari tfx pro-forma net leverag increas
dividend maintain conjunct report compani oper result board
director author quarterli dividend per common share payabl march sharehold
record close busi march
million except per share data
good sold
report record adj gm driven
volum mix restructur pric
sell gener administr
research develop
adj om repres
record compani
compani lower forecast
note million except per share data
compani document stephen inc estim
compani document stephen inc estim
compani document stephen inc
consolid statement incom non-gaap
million except per share data
fiscal period
fiscal period
fiscal period
fiscal period
good sold
sell gener administr
research develop
compani report stephen inc estim
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
